Editor's choice - Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: A systematic review and meta-analysis of phase III trials

European Journal of Vascular and Endovascular Surgery

Volumn 48, Issue 5, 2014, Pages 565-575

  Kakkos, S K ^a   Kirkilesis, G I ^a   Tsolakis, I A ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; PLACEBO; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

BLEEDING; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ORAL DRUG ADMINISTRATION; SECONDARY PREVENTION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; SECONDARY PREVENTION; THIAZOLES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84908349388     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2014.05.001     Document Type: Review

References (34)

1. R. Hull, T. Delmore, E. Genton, J. Hirsh, M. Gent, and D. Sackett Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis N Engl J Med 301 16 1979 855 858
2. C.J. van Dongen, P. Prandoni, M. Frulla, A. Marchiori, M.H. Prins, and B.A. Hutten Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome J Thromb Haemost 3 5 2005 939 942
3. N.H. Hauel, H. Nar, H. Priepke, U. Ries, J.M. Stassen, and W. Wienen Structure-based design of novel potent nonpeptide thrombin inhibitors J Med Chem 45 9 2002 1757 1766
4. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor J Thromb Haemost 3 3 2005 514 521
5. S. Roehrig, A. Straub, J. Pohlmann, T. Lampe, J. Pernerstorfer, and K.H. Schlemmer Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor J Med Chem 48 19 2005 5900 5908
6. D.J. Pinto, M.J. Orwat, S. Koch, K.A. Rossi, R.S. Alexander, and A. Smallwood Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa J Med Chem 50 22 2007 5339 5356
7. T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-Matsumoto, N. Sugiyama, and T. Nagahara DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles J Thromb Haemost 6 9 2008 1542 1549
8. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 24 2009 2342 2352
9. The EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 26 2010 2499 2510
10. The EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 14 2012 1287 1297
11. S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, and D. Baanstra Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N Engl J Med 368 8 2013 709 718
12. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 8 2013 699 708
13. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 2013 799 808
14. The Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 15 2013 1406 1415
15. S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S. Schellong, H. Eriksson, and P. Mismetti Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis Circulation 129 7 2014 764 772
16. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 4 2005 692 694
17. The van Gogh Investigators Idraparinux versus standard therapy for venous thromboembolic disease N Engl J Med 357 11 2007 1094 1104
18. B.D. Fox, S.R. Kahn, D. Langleben, M.J. Eisenberg, and A. Shimony Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials BMJ 345 2012 e7498
19. J.A. Nieto, N.G. Espada, R.G. Merino, and T.C. Gonzalez Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials Thromb Res 130 2 2012 183 191
20. C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, and M.D. Ezekowitz Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 9921 2014 955 962
21. T. van der Hulle, J. Kooiman, P.L. den Exter, O.M. Dekkers, F.A. Klok, and M.V. Huisman Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis J Thromb Haemost 12 3 2014 320 328
22. G. Wasserlauf, S.M. Grandi, K.B. Filion, and M.J. Eisenberg Meta-analysis of rivaroxaban and bleeding risk Am J Cardiol 112 3 2013 454 460
23. G. Ntaios, V. Papavasileiou, H.C. Diener, K. Makaritsis, and P. Michel Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Stroke 43 12 2012 3298 3304
24. F. Dentali, N. Riva, M. Crowther, A.G. Turpie, G.Y. Lip, and W. Ageno Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 20 2012 2381 2391
25. C.D. Seaman, K.J. Smith, and M.V. Ragni Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective Thromb Res 132 6 2013 647 651
26. P. Lefebvre, C.I. Coleman, B.K. Bookhart, S.T. Wang, S.H. Mody, and K.N. Tran Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism J Med Econ 17 1 2014 52 64
27. T. Baglin, R. Luddington, K. Brown, and C. Baglin Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study Lancet 362 9383 2003 523 526
28. P. Prandoni, F. Noventa, A. Ghirarduzzi, V. Pengo, E. Bernardi, and R. Pesavento The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients Haematologica 92 2 2007 199 205
29. B.A. Hutten, and M.H. Prins Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism Cochrane Database Syst Rev 1 2006 CD001367
30. M.R. Southworth, M.E. Reichman, and E.F. Unger Dabigatran and postmarketing reports of bleeding N Engl J Med 368 14 2013 1272 1274
31. I.L. Holster, V.E. Valkhoff, E.J. Kuipers, and E.T. Tjwa New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis Gastroenterology 145 1 2013 105 e15 112 e15
32. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 5 2012 397 402
33. G. Lu, F.R. DeGuzman, S.J. Hollenbach, M.J. Karbarz, K. Abe, and G. Lee A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat Med 19 4 2013 446 451
34. R.D. Hull, J. Liang, and G. Townshend Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review Am J Med 124 8 2011 756 765